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Abstract 
 
 
 
Background: Hypercholesterolaemia has been associated with low bone mineral density 
(BMD) in some but not all studies.  
Objectives: To examine the influence of age, menopausal status and hormone 
replacement therapy (HRT) on the relationship between serum cholesterol and BMD in 
women. 
Patients and measurements: 497 female participants (age range 20 - 81) comprising 
224 premenopausal and 273 postmenopausal women (156 on HRT and 117 no HRT) 
underwent measurement of serum cholesterol and BMD. 
Results: Serum cholesterol was higher and lumbar BMD was lower in 
postmenopausal women not taking HRT compared to women those taking HRT.  
Serum cholesterol was negatively associated with BMD at all measured sites among 
postmenopausal women not taking HRT in univariate regression analysis (all p < 0.05).  
After adjustment for age, BMI, smoking and alcohol consumption, the relationship 
between serum cholesterol and BMD remained significant at the lumbar spine and whole 
body (p < 0.05).  For subjects in the other groups, no significant association between 
serum cholesterol and BMD was found.  A significant interaction of cholesterol with 
HRT was detected among post-menopausal women in the regression analyses (all p < 
0.05).   
Conclusion:  There is a modest inverse relationship between total serum cholesterol and 
whole body and lumbar spine BMD in post-menopausal women.  HRT use appears to 
modify this relationship.  The mechanisms of this relationship require further study. 
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Introduction 
 
Hypercholesterolaemia has been associated with low bone mineral density in some [1-3] 
but not all [4-6] studies.  A number of studies have reported a positive relationship 
between BMD and triglyceride levels[7, 8], while the literature concerning relationships 
between HDL and LDL cholesterol levels and BMD is conflicting[5, 7, 9-13].   
For example, a study of Orozco and colleagues [1] found that early postmenopausal 
women with an atherogenic lipid profile had lower lumbar and femoral BMD and had an 
increased risk of osteopaenia compared to those with a normal lipid profile, suggesting 
that hyperlipidaemia could be associated with osteoporosis. In a longitudinal study in 
postmenopausal women aged 50–75 years, those with the largest increases in serum 
cholesterol showed the greatest decreases in spine BMD independently of change in the 
body mass index [2].  Contradicting these findings, cross-sectional studies by Solomon et 
al. [5]; Wu and colleagues [6] and a prospective study of Samelson et al. [4] found no 
relationship between total serum cholesterol levels and BMD, but there were a number of 
methodological limitations in these latter studies which could affect interpretation.   
 
The existence of a possible link between bone and metabolic pathways has been 
recognised for some time.  Low bone mineral density has been reported to be associated 
with increased risk of cardiovascular mortality [14, 15] and aortic calcification [3, 16, 
17], however, the pathophysiologic mechanisms underlying this association are unknown.  
A longitudinal study reported that in early postmenopausal women, each decrease of one 
standard deviation (SD) in distal forearm bone mineral content was associated with a 2.3-
fold increased risk for cardiovascular death within the next 17 years.  This study also 
estimated that in 70 year old women, a one SD decrease in their BMD Z-score was 
associated with a 1.8-fold increase of cardiovascular death [15].  It was suggested that 
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low bone mass during menopause could be a risk factor for increased cardiovascular 
mortality in later life [15].  Similarly in the Study of Osteoporotic Fractures (SOF), each 
one SD decrease of BMD in the proximal radius was associated with a relative risk of 1.7 
for stroke death in older postmenopausal women [14, 18].  In this study, the association 
was not confounded by history of previous stroke, hypertension, postmenopausal use of 
oestrogen, thiazide use, diabetes mellitus or smoking [14].  
 
The aim of the present study was to examine the relationship between cholesterol 
levels and bone mineral density at various skeletal sites.  Moreover, we sought to 
specifically examine whether or not such relationships are affected by age, menopausal 
status or HRT use. 
 
Materials and Methods  
 
Subjects 
Study subjects were healthy adult twin pairs aged > 18 years recruited as part of the 
Northern Sydney Twin Study at the Department of Rheumatology of the Royal North 
Shore Hospital.  Subjects taking hormone replacement therapy (HRT) were not excluded, 
but such use was recorded. Women who have ever taken HRT for more then 6 months 
within the last 2 years were considered as HRT-users.  Participants, taking statins, 
ezetemibe, gemfibrozil, fenofibrate and bisphosphonates were excluded from the study 
analyses.  The hospital’s Human Research Ethics Committee approved the study.  Some 
of these twin data have been previously reported [19-21].  After providing written 
informed consent, each twin was interviewed separately in accordance with a standard 
questionnaire to collect demographic, lifestyle and medical history data.  Fasting serum 
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total cholesterol, triglycerides and HDL levels were measured and LDL cholesterol levels 
were calculated using standard formula: LDL = Total Cholesterol - HDL - (TG / 5) [22]. 
 
 
Bone Mineral Density and Body Composition Measurements.  
Baseline characteristics included age, height (m), weight (kg), BMI 
(weight/height2, kg/m2), smoking history, alcohol consumption and menopausal status for 
women.   
 
Whole body, lumbar spine (L1-L4) and hip sites were scanned by fan-beam dual-
energy x-ray absorptiometry (DEXA) using a QDR 4500W (Hologic, Waltham, MA. 
USA).  Bone mineral density (BMD) of the whole body (WBBMD), lumbar spine 
(LSBMD), total hip (HIPBMD) and femoral neck (FNBMD) were obtained from DEXA 
scans using standard protocols as previously described [19, 23]. 
Body composition measures, such as total fat mass (TOT FM) and total lean mass 
(TOT LM) were obtained directly from whole body DEXA body composition analysis. 
All scans were analysed by same operator.   
 
Statistical Analysis 
A significant interaction of cholesterol with HRT was detected among post-
menopausal women in the regression analysis of relationship between cholesterol and 
BMD at different skeletal sites (all p < 0.05).  Therefore, the study population was 
divided into three groups: pre-menopausal women, or post-menopausal women who were 
either using or not using HRT. T-tests were used for comparing differences in cholesterol 
and BMD between groups.  Pearson correlations were used to examine the relationship 
between BMD measures and cholesterol.  Linear regression analysis was performed to 
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examine the strength of these relationships after adjusting for potential confounders such 
as age, BMI, smoking history and alcohol intake.  Lack of independence among twin 
family members was taken into account by excluding one of the members of the MZ twin 
pairs and using Generalized Estimating Equations (GEE).  P values of < 0.05 were 
considered significant.  All statistical analyses were performed using SPSS for 
Windows 11.5 (SPSS, Chicago, IL) and Stata 8.2. 
 
 
Results 
There were 556 female twin participants (278 pairs, age range 20 to 81 years) in 
the study. After randomly excluding one member of each MZ twin pair (n = 27), subjects 
taking cholesterol lowering therapy (28) and bisphosphonates (8), there were 497 women 
left for the final analyses, comprising 224 premenopausal and 273 postmenopausal women 
(156 on HRT and 117 no HRT). 
The characteristics of the subjects according to these three groups are shown in 
Table 1.  Post-menopausal women, who have never taken HRT, had significantly higher 
cholesterol levels than post-menopausal women on HRT or pre-menopausal women (6.04 
vs. 5.85, and 5.14 mmol/ l, respectively, p<0.001). They also had lower BMD 
measurements at the lumbar spine compare to the other study groups (0.94, 0.96 and 
1.05g/cm2, respectively; p<0.001).  There was no significant difference in age between 
postmenopausal women who had never taken or those who had taken HRT (58.5 vs 57.9 
years).  Fat mass was higher in postmenopausal women not taking HRT than those taking 
HRT and premenopausal women (26.21, 24.57 and 20.55 kg, respectively; p<0.001) and 
lean mass was higher in premenopausal women (p<0.001). 
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The correlations between cholesterol and BMD at various sites are shown in 
Table 2.  BMD at the lumbar spine and whole body showed statistically significant 
inverse correlations with total cholesterol level but only in post-menopausal women who 
had never taken on HRT (r = -0.236 and r= -0.246, p < 0.05, for lumbar spine and whole 
body, respectively).  Figure 1 shows these relationships for the three groups at the lumbar 
spine site.   
 
Regression analyses for total serum cholesterol, LDL and HDL and bone mineral 
density at different skeletal sites were performed.  The results of univariate analyses 
presented in Table 3 and multivariate analyses adjusting for age, BMI, smoking 
history and alcohol intake are presented in Table 4.  Total serum cholesterol was 
negatively associated with BMD at all sites among postmenopausal women not taking 
HRT in univariate regression analysis (all p < 0.05).  Similar results were found for 
LDL.  After adjustment for age and BMI, smoking and alcohol intake the relationship 
between serum cholesterol and BMD remained significant at the lumbar spine and whole 
body (p = 0.02 and p = 0.002 respectively).  Using the total fat mass instead of BMI did 
not alter the results of the regression.  For subjects in the other groups, no significant 
association between serum cholesterol and BMD was detected. 
 
Discussion 
In univariate analyses, higher total cholesterol level was significantly associated 
with lower BMD at lumbar spine and whole body in postmenopausal women not taking 
HRT.   Moreover, in fully adjusted regression models, the relationship between total 
cholesterol and BMD remained significant in post-menopausal women who had never 
taken HRT.  This was not seen in premenopausal women or in post-menopausal women 
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taking HRT.  Similar results were reported by the large study of Solomon and colleagues 
of subjects participating in the NHANES survey [5].  They found that the association 
between total cholesterol and BMD observed in unadjusted analyses was no longer 
present in fully adjusted models. However the pooling of data for final analyses in the 
study of Solomon at al [5] included both genders, a wide age range and pre- and post-
menopausal women, regardless of HRT use.  Our study suggests HRT use could modify 
relationship between total cholesterol level and BMD among post-menopausal women, 
which needs to be accounted for in any statistical analysis. 
Previous studies of the relationship between BMD and serum cholesterol have 
been conflicting.  Orozco et al [1] studied 52 obese, early menopausal women (mean age 
55 years) with no history of HRT use and found that 29 women with 
hypercholesterolaemia (defined as > 240mmg/dl) had a higher prevalence of low BMD at 
the spine (83% vs 55%) and femoral neck 96.5% vs 38%) than 23 women without 
hypercholesterolaemia. 
 
Samelson et al [4] measured serum cholesterol in 1953-55 in 712 women and 450 
men enrolled in the Framingham study.  Bone density was not measured until 34 years 
later (1988-1989).  Cross-sectional BMD was similar across quartiles of total cholesterol 
in both men and women, except for radial shaft BMD in men, which was lower with 
increasing cholesterol.  Mean duration of oestrogen use was two years in women but it 
was unclear how many women actually used oestrogen and when this was prescribed, 
although since the mean age at baseline was 41.3 years, presumably some use of the 
oestrogen was premenopausal or for oral contraceptive purposes. Current use of HRT at 
the time of BMD measurement was not specified. 
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We have not found any association between total cholesterol and BMD in post-
menopausal women who had a history of HRT use and this may be because HRT use 
affects the relationship by modifying total cholesterol levels.  Most other previous studies 
of the effect of HRT on plasma lipids have reported that oestrogen use lowers LDL 
cholesterol and increases HDL cholesterol [24-26], although the effects on total 
cholesterol have not been reported.  Thomsen et al [27] performed a post hoc analysis of 
133 postmenopausal women who had participated in a randomised trial of varying doses 
of oestradiol plus gestodene versus placebo over 3 years.  Although BMD increases at the 
spine and hip correlated with reductions in total cholesterol, endogenous serum 
cholesterol was high at baseline (6.70 mmol/l) and not associated with BMD of the spine 
and hip.  A positive association has also been reported between the severity of carotid 
atherosclerosis, serum cholesterol and low total body BMD in older postmenopausal 
women [3].  In asymptomatic postmenopausal women, those with lumbar osteoporosis 
have higher coronary calcium scores (indicative of atherosclerosis) than those with 
normal bone density [16]. 
 
Our study is consistent with the study of Tanko et al [2] which found a significant 
inverse correlation between serum cholesterol at the spine but not the hip in 340 
postmenopausal Danish women at baseline.  Moreover when followed over 8 years, those 
women with the largest increases in serum cholesterol showed the greatest decreases in 
BMD.    It is unclear if any women started HRT during the follow-up period of this study.  
The authors concluded this relationship was due to oestrogen deficiency rather than any 
direct influence of serum cholesterol on osteoblast function.  
However in vitro and in vivo studies indicate that cholesterol and its metabolites 
can influence the functional activity of osteoblasts [28, 29].  In mice and rabbits fed with 
atherogenic high-fat diet reduced bone mineralization was observed [30].  In addition, 
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some [31-37], but not all [38, 39] studies have suggested that statins, widely used as 
lipid-lowering agents, offer benefits in the preservation of bone mass and the prevention 
of osteoporotic fractures.  Why such an effect would be evident in the spine but not the 
hip remains unclear, however the relative composition in terms of trabecular versus 
cortical bone varies at these sites and we and others have previously reported this 
differential effect on other bone related endpoints. For example we have shown that total 
body fat mass is related to lumbar spine BMD but not hip BMD in younger subjects [20]. 
A number of studies have reported a positive relationship between BMD and 
triglyceride levels[7, 8], while the literature concerning relationships between HDL and 
LDL cholesterol levels and BMD is conflicting[5, 7, 9-13].  While D’Amelio et al. [10] 
found an inverse relation, Yamaguchi et al.[13] reported a positive relationship, and Cui 
et al.[7] and Poli et al. [12] found no relationship. Aside from genetic differences, one 
possible explanation may be the importance of oestrogen concentration in these groups; 
most studies have explored relationships in post-menopausal women, but time since 
menopause varies considerably in different groups, and different studies have taken 
varying approaches to HRT, some excluding any women on such 
 
Our study has several strengths and limitations. We measured a large number of 
subjects in a variety of menopausal groupings.  However we only measured total 
cholesterol, not sub-fractions such as LDL or HDL, although this has been reported by 
others.  For example Adami et al [40] studied 236 pre or postmenopausal women 
attending an osteoporosis clinic as well as 265 men an 481 women from the community 
and observed a negative relationship between spine and hip BMD and HDL cholesterol in 
both groups but a positive relationship with LDL cholesterol.  Oestrogen use in the last 
12 months was an exclusion criterion in that study.  Poli et al [12] studied 1303 
postmenopausal women attending a menopause clinic, none of whom had taken HRT for 
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at least 6 months, and found women with increased LDL cholesterol were more likely to 
have reductions in BMD but no significant relationship with HDL cholesterol.  
Accordingly the relationship between cholesterol sub-fractions and BMD at different 
sites clearly needs further study.  
 
In conclusion, we observed a modest inverse relationship between total serum cholesterol 
and BMD at the spine and not the hip in post menopausal women who had never taken 
HRT.  HRT use appears to act to reverse this relationship between total serum cholesterol 
and BMD at the spine and needs to be taken into account in future studies.  Because 
oestrogen can have direct effects on bone and cholesterol metabolism, the mechanisms of 
the relationship requires further evaluation.    
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Table 1.  Baseline characteristics of study population 
 
Mean (SD) 
Women Post-
menopausal  No HRT 
(N=117) 
Women Post-
menopausal   on HRT 
(N=156) 
Women Pre-
menopausal   
(N=224) 
p* p** 
      
Age (years) 58.48 (8.72) 57.92 (7.12) 35.81 (9.24) P <0.001 0.11 
Weight (kg) 76.45 (12.27) 75.99 (10.88) 71.56 (11.31) P <0.001 0.74 
Height (m) 1.60 (0.06) 1.62 (0.06) 1.65 (0.06) P <0.001 0.05 
BMI (kg/m2) 29.83 (5.16) 29.09 (4.47) 26.37 (4.44) P <0.001 0.20 
      
Total cholesterol (mmol/l) 6.04 (1.01) 5.85 (0.97) 5.14 (0.91) P <0.001 0.13 
LDL (mmol/l)  4.45 (1.06) 4.29 (1.07) 3.61 (0.96) P <0.001 0.25 
Triglycerides (mmol/l) 1.51 (0.88) 1.54 (0.69) 1.21 (0.74) P <0.001 0.72 
HDL (mmol/l) 1.31 (0.51) 1.27 (0.59) 1.33 (0.41) 0.67 0.52 
      
BMD (g/cm2)      
Lumbar spine (L1-L4) (g/cm2) 0.944 (0.153) 0.958 (0.144) 1.047 (0.114) P <0.001 0.45 
Total Hip (g/cm2) 0.902 (0.120) 0.892 (0.131) 0.970 (0.122) P <0.001 0.50 
Femoral Neck (g/cm2) 0.759 (0.119) 0.750 (0.121) 0.849 (0.116) P <0.001 0.53 
Whole Body (g/cm2) 1.061 (0.116) 1.080 (0.109) 1.147 (0.095) P <0.001 0.16 
      
Body Composition      
Total Fat mass (kg) 26.21 (9.42) 24.57 (8.57) 20.55 (9.26) P <0.001 0.13 
Total Lean Mass (kg) 38.77 (4.55) 39.27 (4.67) 41.41 (4.89) P <0.001 0.38 
      
Smoking      
Never smoked 78 86 136   
Ever Smoked 39 70 88   
      
Alcohol consumption      
Light (< 5 units per week) 96 114 176   
Moderate (6-15 units per week) 18 38 41   
Heavy (more than 15 units per week) 3 4 7   
      
 
p*   - P-values for the results of T-test between post-menopausal women with no HRT history and premenopausal women 
p** - P-values for the results of T-test between post-menopausal women with no HRT history  and post-menopausal women on HRT  
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Table 2. Correlations between serum cholesterol and bone mineral density at various skeletal sites 
 
 
 
  
Post-menopausal women No 
HRT (n=117) 
Post-menopausal women on 
HRT (n=156) 
Pre-menopausal women          
(n=224) 
  r P r P r P 
       
Lumbar spine BMD -0.20 0.03 -0.002 0.99 0.06 0.34 
       
Total hip BMD -0.12 0.20 -0.003 0.97 0.005 0.94 
       
Femoral neck BMD -0.14 0.13 -0.01 0.90 0.02 0.79 
       
Whole body BMD -0.21 0.02 -0.06 0.47 0.05 0.48 
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Figure 1. Correlations between total serum cholesterol and Lumbar spine BMD in  
 
Post-menopausal women, no HRT (r= - 0.200; p< 0.05) 
 
Post-menopausal women, on HRT (r= - 0.002; p=0.99) 
  
 
Pre-menopausal women (r=0.060; p=0.34) 
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Table 3. Results of the Regression Analysis for serum cholesterol and bone mineral density at various skeletal 
sites 
 
  
Post-Menopausal women 
No HRT (n=117) 
Post-Menopausal 
women on  HRT 
(n=156) 
Pre-Menopausal women 
(n=224) 
  e^coef (95% CI) P e^coef (95% CI) P e^coef (95% CI) P 
       
Lumbar spine BMD        
Unadjusted 0.97 (0.94-0.99) <0.01 1.00 (0.98-1.02) 0.81 1.01 (0.99-1.02) 0.3 
Adjusted for age, BMI, smoking and alcohol 
consumption 0.97 (0.94-1.00) 0.02 1.01 (0.99-1.03) 0.21 1.00 (0.99-1.02) 0.61 
       
Total hip BMD       
Unadjusted 0.98 (0.96-1.00) 0.04 1.00 (0.99-1.02) 0.91 1.00 (0.98-1.02) 0.81 
Adjusted for age, BMI, smoking and alcohol 
consumption 0.99 (0.97-1.01) 0.19 1.01 (0.99-1.02) 0.47 1.00 (0.98-1.02) 0.98 
       
Femoral Neck BMD       
Unadjusted 0.98 (0.96-0.99) <0.01 1.00 (0.98-1.02) 0.95 1.00 (0.99-1.02) 0.77 
Adjusted for age, BMI, smoking and alcohol 
consumption 0.99 (0.97-1.00) 0.16 1.00 (0.99-1.02) 0.59 1.00 (0.98-1.02) 0.81 
       
Whole body BMD        
Unadjusted 0.97 (0.96-0.99) 0.001 1.00 (0.98-1.01) 0.73 1.00 (0.99-1.02) 0.52 
Adjusted for age, BMI, smoking and alcohol 
consumption 0.98 (0.96-1.00) 0.02 1.00 (0.99-1.02) 0.63 1.00 (0.99-1.02) 0.7 
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NEW Table 3. Results of the Crude Regression Analysis for total serum cholesterol, HDL and LDL and bone 
mineral density at various skeletal sites 
 
  
Post-Menopausal women No HRT 
(n=105) 
Post-Menopausal women on  
HRT (n=144) 
Pre-Menopausal women       
(n=202) 
  B (95% CI) P B (95% CI) P B (95% CI) P 
       
Lumbar spine BMD        
Tot cholesterol  -0.036 (-0.06 - -0.012) 0.004 0.003 (-0.018 - 0.023) 0.808 0.008 (-0.008 - 0.024) 0.298 
LDL -0.033 (-0.058 - -0.009) 0.008 0.009 (-0.013 - 0.030) 0.427 0.015 (-0.007 - 0.031) 0.061 
Triglycerides -0.026 (-0.057 - 0.006) 0.112 0.031 (-0.019 - 0.064) 0.064 0.011 (-0.003 - 0.026) 0.127 
HDL -0.012 (-0.060 - 0.037) 0.639 -0.036 (-0.073 - 0.022) 0.065 -0.056 (-0.092 - -0.017) 0.005 
       
Total hip BMD       
Tot cholesterol -0.018 (-0.036 - -0001) 0.036 0.001 (-0.015 - 0.017) 0.912 0.002 (-0.016 - 0.020) 0.810 
LDL -0.018 (-0.036 - -0.00003) 0.050 0.012 (-0.005 - 0.028) 0.161 0.010 (-0.007 - 0.026) 0.246 
Triglycerides -0.005 (-0.028 - 0.018) 0.668 0.020 (-0.016 - 0.057) 0.279 0.023 (0.002 - 0.044) 0.031 
HDL -0.011 (-0.055 - 0.032) 0.608 -0.038 (-0.067 - -0.009) 0.010 -0.038 (-0.074 - -0.028) 0.034 
       
Femoral Neck BMD       
Tot cholesterol -0.023 (-0.040 - -0.006) 0.007 -0.001 (-0.017 - 0.016) 0.950 0.003 (-0.015 - 0.020) 0.766 
LDL -0.021 (-0.039 - -0.003) 0.026 0.012 (-0.004 - 0.027) 0.144 0.010 (-0.006 - 0.026) 0.207 
Triglycerides -0.010 (-0.032 - 0.011) 0339 0.019 (-0.015 - 0.053) 0.285 0.014 (-0.003 - 0.032) 0.096 
HDL -0.009 (-0.052 - 0.035) 0.696 -0.045 (-0.072 - -0.018) 0.001 -0.046 (-0.081 - -0.011) 0.009 
       
Whole body BMD        
Tot cholesterol -0.028 (-0.045 - -0.012) 0.001 -0.003 (-0.018 - 0.013) 0.726 0.004 (-0.009 - 0.017) 0.516 
LDL -0.030 (-0.048 - -0.012) 0.001 0.005 (-0.011 - -0.021) 0.549 0.010 (-0.003 - 0.022) 0.142 
Triglycerides -0.033 (-0.054 - -0.012) 0.002 0.014 (-0.011 - 0.039) 0.275 0.011 (-0.005 - 0.026) 0.191 
HDL 0.025 (-0.018 - 0.067) 0.262 -0.033 (-0.062 - -0.005) 0.020 -0.035 (-0.067 - -0.036) 0.029 
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NEW Table 4. Results of the Multiple Regression Analysis  for total serum cholesterol, HDL and LDL and bone 
mineral density at various skeletal sites 
 
  
Post-Menopausal women No 
HRT  
Post-Menopausal women on  
HRT  Pre-Menopausal women        
  B (95% CI) P B (95% CI) P B (95% CI) P 
       
Lumbar spine BMD  (n=117)  (n=156)  (n=224)  
Total cholesterol  -0.030 (-0.057 - -0.004) 0.023 0.013 (-0.008 - 0.034) 0.214 0.004 (-0.012 - 0.021) 0.610 
 (n=105)  (n=144)  (n=202)  
LDL -0.044 (-0.076 - -0.011) 0.009 0.009 (-0.014 - 0.032) 0.452 0.005 (-0.013 - 0.024) 0.574 
Triglycerides -0.007 (-0.046 - 0.032) 0.722 0.009 (-0.029 - 0.047) 0.654 0.005 (-0.025 - 0.015) 0.613 
HDL -0.119 (-0.179 - 0.058) <0.001 -0.018 (-0.061 - 0.024) 0.399 -0.061 (-0.112 - -0.010) 0.020 
       
Total hip BMD (n=117)  (n=156)  (n=224)  
Total cholesterol -0.012 (-0.031 - 0.006) 0.190 0.006 (-0.010 - 0.021) 0.474 -0.0002 (-0.018 - 0.018) 0.984 
 (n=105)  (n=144)  (n=202)  
LDL -0.018 (-0.044 - 0.008) 0.183 0.011 (-0.007 - 0.030) 0.236 -0.00004 (-0.019 - 0.019) 0.996 
Triglycerides -0.005 (-0.041 - 0.031) 0.794 -0.023 (-0.063 - 0.017) 0.260 0.014 (-0.014 - 0.042) 0.319 
HDL -0.043 (-0.084 - 0.002) 0.041 -0.018 (-0.049 - 0.012) 0.241 -0.031 (-0.081 - 0.018) 0.217 
       
Femoral Neck BMD (n=117)  (n=156)  (n=224)  
Total cholesterol -0.011 (-0.027 - 0.004) 0.158 0.005 (-0.012 - 0.021) 0.592 0.002 (-0.015 - 0.020) 0.807 
 (n=105)  (n=144)  (n=202)  
LDL -0.015 (-0.040 - 0.010) 0.250 0.008 (-0.010 - 0.025) 0.880 0.002 (-0.015 - 0.020) 0.790 
Triglycerides 0.0003 (-0.033 - 0.034) 0.986 -0.017 (-0.054 - 0.020) 0.369 0.004 (-0.017 - 0.026) 0.702 
HDL -0.052 (-0.091 - 0.013) 0.009 -0.034 (-0.064 - -0.005) 0.024 -0.048 (-0.097 - 0.0004) 0.052 
       
Whole body BMD  (n=117)  (n=156)  (n=224)  
Total cholesterol -0.022 (-0.040 - -0.004) 0.018 0.004 (-0.012 - 0.019) 0.634 0.003 (-0.011 - 0.016) 0.703 
 (n=105)  (n=144)  (n=202)  
LDL -0.022 (-0.046 - 0.001) 0.061 0.003 (-0.013 - 0.020) 0.708 0.003 (-0.011 - 0.018) 0.668 
Triglycerides -0.010 (-0.041 - 0.021) 0.545 -0.007 (-0.037 - 0.022) 0.625 0.003 (-0.015 - -0.002) 0.751 
HDL -0.036 (-0.084 - 0.011) 0.132 -0.030 (-0.060 - 0.001) 0.057 -0.041 (-0.081 - -0.002) 0.039 
              
 
Total cholesterol - Adjusted for age, BMI, smoking and alcohol consumption 
LDL - Adjusted for age, BMI, HDL, Triglycerides, smoking and alcohol consumption 
HDL - Adjusted for age, BMI, LDL,Triglycerides, smoking and alcohol consumption 
